Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Metformin’s Impact in DLBCL Patients with Diabetes

Leuk Lymphoma; ePub 2016 Oct 5; Alkhatib, et al

Publish date:: October 19, 2016

Metformin may improve response and progression-free survival in people with diabetes who also have diffuse large B-cell lymphoma (DLBCL), according to a case control study involving 24 individuals.

All participants had diabetes and were newly diagnosed with DLBCL. Half received metformin and the other half did not. Investigators looked at overall response rate, complete remission rate, as well as progression-free and overall survival. Among the results:

Overall response, complete remission, and progression-free survival were significantly improved in the metformin group, compared with those who did not receive it.
Overall survival rates were not different.

Citation:

Alkhatib Y, Abdel Rahman Z, Kuriakose P. Clinical impact of metformin in diabetic diffuse large B-cell lymphoma patients: A case-control study. [Published online ahead of print October 5, 2016]. Leuk Lymphoma. doi:10.1080/10428194.2016.1239822.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Aggressive Lymphomas

Study Halted; ‘Hyperprogression’ Seen With Nivolumab for R/R PTCL,

CAR T-Cell Therapy Found Safe, Effective For HIV-Associated Lymphoma,

Bispecific CAR T-cell Therapy Yields Complete Responses in Relapsed/Refractory non-Hodgkin Lymphomas,

5F9 Plus Rituximab Take a Bite Out of Drug-Resistant NHL,

‘Encouraging’ Responses Seen With Durvalumab Plus R-CHOP in DLBCL,